Both GSK plc (GSK Quick QuoteGSK - Free Report) and Moderna (MRNA Quick QuoteMRNA - Free Report) are seeking to drive long-term growth through innovation in vaccines and treatments for serious diseases, but they are pursuing different strategies.

While Moderna is expanding beyond vaccines into oncology, including a personalized mRNA-based cancer therapy being developed in partnership with Merck (MRK Quick QuoteMRK - Free Report) , GSK is building on its established pharmaceutical and vaccine business while advancing its own oncology pipeline.

But which stock offers greater growth potential today? Let’s compare the two companies’ fundamentals, growth prospects and valuations to determine which stock makes the stronger investment case.

The Case for GSK

The British drugmaker boasts a diversified portfolio across vaccines, specialty medicines and general medicines, along with a broad geographic presence.

The company is witnessing solid momentum in its Specialty Medicines business, its largest revenue-generating segment. During the first nine months of 2026, sales in the franchise rose 14% at constant exchange rates (CER), driven by double-digit growth across all therapy areas: HIV, Respiratory, Immunology & Inflammation (RI&I) and Oncology. GSK remains on track to deliver low-double-digit sales growth in Specialty Medicines for full-year 2026 at CER.

Key contributors to the segment include established products such as Nucala, Dovato and Benlysta, alongside long-acting HIV medicines Cabenuva and Apretude and newer oncology drugs Jemperli, Blenrep and Ojjaara. Strong patient demand for these treatments is supporting the franchise’s continued growth. Building on this momentum, GSK expects Specialty Medicines to account for more than 50% of total revenues by 2031, up from over 40% currently.

GSK is stepping up R&D investment to advance promising long-acting and specialty medicines across RI&I, Oncology and HIV. In 2025, the company strengthened its pipeline through more than 10 acquisitions and discovery collaborations. This momentum continued in 2026 with acquisitions such as 35Pharma and Nuvalent.

These investments are bolstering GSK’s growth pipeline. The company said it has more than doubled the number of phase II and phase III assets with blockbuster potential since 2022. GSK is targeting 22 phase III trial starts in 2026, with 18 already initiated.

GSK is also expanding its presence in next-generation vaccines. Following positive phase II results, the company has advanced its investigational mRNA-based seasonal flu vaccine into phase III development. Unlike Moderna’s recently approved mRNA flu vaccine, which targets hemagglutinin (HA), GSK’s candidate is designed to target both HA and neuraminidase (NA), two key proteins on the flu virus. This approach could offer a differentiated product in the seasonal flu vaccine market, although the candidate’s commercial potential will depend on successful late-stage studies.

Supported by its new product launches and robust pipeline progress, GSK expects sales to be more than £40 billion by 2031.

However, GSK faces its share of headwinds. Patents protecting dolutegravir, which is the backbone of several leading HIV medicines, including Tivicay, Triumeq and Dovato, are expected to begin expiring in major markets during 2028-2030, opening the door for generic competition. The company also faces pressure in the General Medicines segment, where sales declined year-to-date. Pipeline setbacks, such as the recent discontinuation of camlipixant in chronic cough due to limited efficacy, also raise concerns. Meanwhile, its latest results highlighted near-term pressure on the vaccine business, with weaker sales of shingles, RSV and influenza vaccines.

The Case for MRNA

Moderna has evolved considerably since becoming a commercial-stage company with its COVID-19 vaccine, Spikevax. The company has since expanded its respiratory vaccine portfolio with mResvia, its RSV vaccine, and mFlusiva, its standalone seasonal influenza vaccine. It also received European Union marketing authorization for mCombriax, a combination vaccine targeting both influenza and COVID-19.

This gives Moderna a presence across three major respiratory vaccine categories and should gradually reduce its reliance on COVID demand. The broader respiratory pipeline also provides additional avenues for expansion, with vaccines for norovirus and bird flu in late-stage development.

Moderna is also expanding beyond respiratory diseases, with oncology emerging as a potential growth driver. In August, the company and partner Merck announced positive top-line results from the phase III INTerpath-001 study of their personalized mRNA cancer therapy, intismeran autogene. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected, high-risk (Stage IIB-IV) melanoma.

However, when detailed results were released in October, investors were less impressed. The combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% compared with Keytruda alone. However, investors were underwhelmed, comparing the latter result with the 59% risk reduction reported in an earlier phase IIb study. With expectations already elevated following Moderna’s sharp rally, the results triggered a recent ‘sell-the-news’ reaction.

Despite the market disappointment, intismeran remains an important potential catalyst for Moderna's oncology ambitions. Moderna and Merck are advancing intismeran across nine phase II and phase III studies spanning multiple tumor types, including non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. The goal is to determine whether the approach that showed promise in melanoma can be replicated across different tumor types.

Moderna's oncology pipeline extends beyond intismeran. The company is developing mRNA-based cancer antigen therapies, a T-cell engager and a cell-therapy enhancer. These programs could provide additional avenues for growth if they demonstrate clinical and commercial potential. Beyond oncology, Moderna is applying its platform to other therapeutic areas, including rare diseases and autoimmune disorders.

However, competition remains a concern. Moderna faces established competitors across the respiratory markets it targets. In COVID-19 vaccines, it competes with Pfizer (PFE Quick QuotePFE - Free Report) /BioNTech and Sanofi. In RSV, mResvia competes with Pfizer's Abrysvo and GSK's Arexvy, while the seasonal influenza market is already well established, with Sanofi, CSL Seqirus and GSK among the major players. This competitive landscape could make it challenging for Moderna to translate its newer products into significant market share.

Pipeline setbacks pose another risk for the stock. Moderna recently announced that a late-stage study of its norovirus vaccine did not meet the statistical criteria for early success at the interim analysis. This prompted the company to prepare an additional cohort before reaching a final decision. Such setbacks highlight the inherent risks associated with the company’s broad pipeline and show that a large number of programs does not guarantee successful commercialization.

How Do Estimates Compare for GSK & MRNA?

The Zacks Consensus Estimate for GSK’s 2026 sales and EPS implies a year-over-year increase of 3.6% and 5.3%, respectively.

Bottom-line estimates for 2026 and 2027 have declined over the past 30 days.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Moderna’s 2026 sales suggests 8.3% year-over-year growth, while the company’s loss per share is expected to widen by 17.4%.

Loss per share estimates for 2026 have risen over the past 30 days, while the same for 2027 have narrowed.

Image Source: Zacks Investment Research

Price Performance and Valuation of GSK & MRNA?

Year to date, shares of Moderna have skyrocketed 626%, while those of GSK have lost nearly 1%. In comparison, the industry has climbed more than 7%, as seen in the chart below.

Image Source: Zacks Investment Research

From a valuation standpoint, MRNA is trading at a significant premium compared to GSK, going by the price/sales (P/S) ratio. Moderna’s shares currently trade at 33.23 times forward 12-month sales, higher than 2.15 times for GSK.

Image Source: Zacks Investment Research

Which Is a Better Pick?

GSK and Moderna carry a Zacks Rank #3 (Hold) each, which makes choosing one over the other difficult. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, GSK appears to be the more compelling choice for investors seeking a combination of growth, income and relative valuation support. The company continues to deliver sales and core earnings growth, driven primarily by its fast-growing Specialty Medicines business. Although vaccine sales weakened in the third quarter, this was not entirely unexpected as GSK had previously indicated that its full-year 2026 outlook calls for the segment to be broadly stable or grow at a low-single-digit rate. Its deep pipeline — spanning vaccines, respiratory and infectious diseases, oncology and immunology — provides additional avenues for long-term expansion.

Moderna, meanwhile, offers significant longer-term potential, particularly in oncology, but its newer products and pipeline still need to demonstrate their ability to generate sustained commercial growth. Its profitability outlook remains challenging, and its shares have rallied sharply, leaving them trading at a substantial premium to GSK based on forward sales. At such an elevated valuation, Moderna has less room for disappointment if commercialization takes longer than expected.

Unlike Moderna, GSK also offers a dividend, providing investors with an additional source of returns.